Results 221 to 230 of about 56,712 (295)

Absence of Barrett's esophagus in neurologically normal children with gastroesophageal reflux disease

, 2001
Hashem B. El‐Serag, Mark A. Gilger, Linda Rabeneck   +2 more
openalex   +1 more source

Clinical Characteristics and Outcomes of Incomplete Cardia Reconstruction Cases Following Multiple Anti‐reflux Mucosectomy/Anti‐reflux Mucosal Ablation Treatments

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Introduction Anti‐reflux mucosectomy (ARMS) and anti‐reflux mucosal ablation (ARMA) are novel endoscopic treatments for proton pump inhibitor or potassium‐competitive acid blocker‐refractory gastroesophageal reflux disease. These procedures induce scarring of the artificial ulcer at the gastric cardia, which tightens the enlarged cardiac ...
Ippei Tanaka, Haruhiro Inoue, Mayo Tanabe, Yoshiaki Kimoto, Kei Ushikubo, Kazuki Yamamoto, Yohei Nishikawa, Nikko Theodore Valencia Raymundo, Kazuya Sumi   +8 more
wiley   +1 more source

Response to Commentary on "Sedentary Leisure Behaviour, Physical Activity, and Gastroesophageal Reflux Disease: Evidence From a Mendelian Randomization Analysis". [PDF]

Health Sci Rep
Lu S, Li X, Song Y.
europepmc   +1 more source

Complications of Endoscopic Pressure Study Integrated System: Review of 1205 Cases in 10 Years’ Experience

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Background and Aims The Endoscopic Pressure Study Integrated System (EPSIS) is a novel endoscopic tool to assess lower esophageal sphincter (LES) function by monitoring intragastric pressure (IGP) through insufflation. While previous studies have confirmed its diagnostic utility for LES dysfunction‐related disorders such as gastroesophageal ...
Miyuki Iwasaki, Ippei Tanaka, Haruhiro Inoue, Masachika Saino, Kei Ushikubo, Kazuki Yamamoto, Yohei Nishikawa, Kaori Owada, Satoshi Abiko, Mayo Tanabe   +9 more
wiley   +1 more source

Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment. [PDF]

BMC Gastroenterol
Dong P, Lin L, Sun K, Tang F, Li Q, Zhou X, Liu F, Yang Z, Li J, Jiang L, Zhao P, Sun X, Wang Q.   +12 more
europepmc   +1 more source

Prenatal Brain Abnormalities in Sodium‐Dependent Multivitamin Transporter Deficiency

American Journal of Medical Genetics Part A, Volume 197, Issue 9, September 2025.
ABSTRACT In treatable neurometabolic disorders, early diagnosis and prompt initiation of treatment are key to improved survival and outcomes. Biallelic variants in SLC5A6 cause sodium‐dependent multivitamin transporter deficiency (OMIM # 618973), which is treatable with high‐dose pantothenic acid, biotin, and alpha lipoic acid.
Eri Ogawa, Kenjiro Kosaki, Toshiki Takenouchi   +2 more
wiley   +1 more source

Effectiveness of an educational program about lifestyle habits on patients' knowledge with gastroesophageal reflux disease. [PDF]

J Educ Health Promot
Mohammed Ali BR, Atiyah HH.
europepmc   +1 more source

Effect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction

Annals of Noninvasive Electrocardiology, Volume 30, Issue 5, September 2025.
Sodium‐glucose cotransporter‐2 inhibitor confers cardioprotective effects in patients with left ventricular systolic dysfunction and may attenuate the risk of sudden cardiac death through its antiarrhythmic properties. However, the precise mechanisms underpinning the antiarrhythmic potential of SGLT2 inhibitors remain incompletely characterized.
Yusuf Kayhan, Hakan Kaya, Veysi Kavalci, Sabri Abus, Kadir Biyikli, Sezer Markirt, Cemil Can, Erkan Markirt, Deniz Merde Özdemir   +8 more
wiley   +1 more source

Dysregulated Proteostasis-induced Ferroptosis in Gastroesophageal Reflux Disease: Hero or Villain? [PDF]

Cell Mol Gastroenterol Hepatol
Wang DH.
europepmc   +1 more source

Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

Diabetes, Obesity and Metabolism, Volume 27, Issue 9, Page 4915-4926, September 2025.
Abstract Aims This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity. Materials and Methods Eligible participants (aged 18–75 years; with obesity, without diabetes)
Clare Buckeridge, Sonia Cobain, Harold E. Bays, Osamu Matsuoka, Yasushi Fukushima, Patricia Halstead, Nikolaos Tsamandouras, Nicole Sherry, Donal N. Gorman, Aditi R. Saxena   +9 more
wiley   +1 more source